Isembyld (apitegromab) is a monoclonal antibody indicated for the treatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are receiving an SMN2-targeted treatment.
Unlike therapies that primarily address the underlying SMN protein deficiency, apitegromab is designed to target muscle loss by inhibiting the activation of myostatin, a protein that limits muscle growth. As the first approved therapy specifically designed to target muscle loss in spinal muscular atrophy, Isembyld offers a complementary treatment approach alongside SMN2-targeted therapies.
By addressing muscle function and wasting, it aims to improve motor outcomes in patients who continue to experience physical limitations despite disease-modifying treatment. Its mechanism represents an important expansion of the therapeutic landscape for SMA.
